Literature DB >> 28235956

Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines.

Eleanor L Woodward1, Andrea Biloglav1, Naveen Ravi1, Minjun Yang1, Lars Ekblad2, Johan Wennerberg3, Kajsa Paulsson4.   

Abstract

Anaplastic thyroid cancer (ATC) is a highly malignant disease with a very short median survival time. Few studies have addressed the underlying somatic mutations, and the genomic landscape of ATC thus remains largely unknown. In the present study, we have ascertained copy number aberrations, gene fusions, gene expression patterns, and mutations in early-passage cells from ten newly established ATC cell lines using single nucleotide polymorphism (SNP) array analysis, RNA sequencing and whole exome sequencing. The ATC cell line genomes were highly complex and displayed signs of replicative stress and genomic instability, including massive aneuploidy and frequent breakpoints in the centromeric regions and in fragile sites. Loss of heterozygosity involving whole chromosomes was common, but there were no signs of previous near-haploidisation events or chromothripsis. A total of 21 fusion genes were detected, including six predicted in-frame fusions; none were recurrent. Global gene expression analysis showed 661 genes to be differentially expressed between ATC and papillary thyroid cancer cell lines, with pathway enrichment analyses showing downregulation of TP53 signalling as well as cell adhesion molecules in ATC. Besides previously known driver events, such as mutations in BRAF, NRAS, TP53 and the TERT promoter, we identified PTPRD and NEGR1 as putative novel target genes in ATC, based on deletions in six and four cell lines, respectively; the latter gene also carried a somatic mutation in one cell line. Taken together, our data provide novel insights into the tumourigenesis of ATC and may be used to identify new therapeutic targets.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  gene expression; molecular genetics; thyroid

Mesh:

Year:  2017        PMID: 28235956     DOI: 10.1530/ERC-16-0522

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  9 in total

1.  Epstein-Barr virus induces morphological and molecular changes in thyroid neoplastic cells.

Authors:  Jacqueline Fátima Martins Almeida; José Luiz Proenca-Modena; Natássia Elena Bufalo; Karina Colombera Peres; Elisângela de Souza Teixeira; Larissa Teodoro; Raíssa Marques Beck; Ana Paula Moraes; Alfio José Tincani; Clarice Weis Arns; Laura Sterian Ward
Journal:  Endocrine       Date:  2020-03-12       Impact factor: 3.633

Review 2.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

3.  Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.

Authors:  George R Uhl; Maria J Martinez; Paul Paik; Agnieszka Sulima; Guo-Hua Bi; Malliga R Iyer; Eliot Gardner; Kenner C Rice; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-22       Impact factor: 11.205

4.  GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.

Authors:  Xiaotian Yuan; Ninni Mu; Na Wang; Klas Strååt; Anastasios Sofiadis; Yanxia Guo; Adam Stenman; Kailin Li; Guanghui Cheng; Lu Zhang; Feng Kong; Lars Ekblad; Johan Wennerberg; Inga-Lena Nilsson; C Christofer Juhlin; Catharina Larsson; Dawei Xu
Journal:  Oncogene       Date:  2018-09-04       Impact factor: 9.867

5.  Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.

Authors:  Viswanath Gunda; Benjamin Gigliotti; Dorothy Ndishabandi; Tameem Ashry; Michael McCarthy; Zhiheng Zhou; Salma Amin; Gordon J Freeman; Alessandro Alessandrini; Sareh Parangi
Journal:  Br J Cancer       Date:  2018-10-17       Impact factor: 7.640

6.  Network analysis reveals essential proteins that regulate sodium-iodide symporter expression in anaplastic thyroid carcinoma.

Authors:  Hassan Rakhsh-Khorshid; Hilda Samimi; Shukoofeh Torabi; Sayed Mahmoud Sajjadi-Jazi; Hamed Samadi; Fatemeh Ghafouri; Yazdan Asgari; Vahid Haghpanah
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

7.  IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis.

Authors:  Jacob Haase; Danny Misiak; Marcus Bauer; Nikolaos Pazaitis; Juliane Braun; Rebecca Pötschke; Alexander Mensch; Jessica Lilian Bell; Henning Dralle; Udo Siebolts; Claudia Wickenhauser; Kerstin Lorenz; Stefan Hüttelmaier
Journal:  Mod Pathol       Date:  2020-07-27       Impact factor: 7.842

8.  Gene master regulators of papillary and anaplastic thyroid cancers.

Authors:  Dumitru A Iacobas; Neha Y Tuli; Sanda Iacobas; John K Rasamny; Augustine Moscatello; Jan Geliebter; Raj K Tiwari
Journal:  Oncotarget       Date:  2017-12-19

9.  Clinic-pathologic Features and Prognostic Analysis of Thyroid Cancer in the Older Adult: A SEER Based Study.

Authors:  Li-Ye Shi; Jiang Liu; Lu-Jiao Yu; Yi-Ming Lei; Sean X Leng; Hai-Yan Zhang
Journal:  J Cancer       Date:  2018-07-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.